Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 33-45, March 2010

Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells

  • Rajendra N. Damle, Ph.D (Assistant Investigator, The Feinstein Institute for Medical Research)

      Affiliations

    • The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    • Department of Medicine, NYU School of Medicine, NY, USA
  • ,
  • Carlo Calissano, M.D. (Postdoctoral Fellow, The Feinstein Institute for Medical Research)

      Affiliations

    • The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
  • ,
  • Nicholas Chiorazzi, M.D. (Investigator and Center Head, The Feinstein Institute for Medical Research)

      Affiliations

    • The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    • Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA
    • Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 516 562 1090; Fax: +1 516 562 1011.

B cell-type chronic lymphocytic leukaemia (CLL) has long been considered a disease of resting lymphocytes. However, cell surface and intracellular phenotypes suggest that most CLL cells are activated cells, although only a small subset progresses beyond the G1 stage of the cell cycle. In addition, traditional teaching says that CLL cells divide rarely, and therefore the build-up of leukaemic cells is due to an inherent defect in cell death. However, in vivo labelling of CLL cells indicates a much more active rate of cell birth than originally estimated, suggesting that CLL is a dynamic disease.

Here we review the observations that have led to these altered views of the activation state and proliferative capacities of CLL cells and also provide our interpretation of these observations in light of their potential impact on patients.

Keywords: B lymphocyte, chronic lymphocytic leukaemia, cell proliferation, kinetics, antigen receptor, antigen

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(10)00009-5

doi:10.1016/j.beha.2010.02.001

Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 33-45, March 2010